In combination with the medicines pomalidomide and dexamethasone in people who have received at least two prior medicines to treat multiple myeloma, including lenalidomide and a proteasome inhibitorДЄlone in people who have received at least three prior medicines, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent In combination with the medicines carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma In combination with the medicines bortezomib and dexamethasoneВ in people who have received at least one prior medicine to treat multiple myeloma

In combination with the medicines bortezomib, thalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) In combination with the medicines bortezomib, melphalan, and prednisone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) In combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) and in people whose multiple myeloma has come back or did not respond to treatment who have received at least one prior medicine to treat multiple myeloma If you are having any difficulty accessing cost support through the Janssen CarePath Savings Program, please contact us at 844-55DARZA (84).ДARZALEX В® is a prescription medicine used to treat adults with multiple myeloma: The cost support is meant solely for patients-not health plans and/or their partners. This benefit is intended to help eligible patients afford their out-of-pocket obligations as set by their health plans. We provide cost support directly to patients through the Janssen CarePath Savings Program. Program does not cover the cost to give you your infusion. Terms expire at the end of each calendar year and may change. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. With the Janssen CarePath Savings Program for DARZALEX В®, eligible patients pay $5 for each infusion for your medication costs, with a $20,000 maximum program benefit each calendar year. Depending on your health insurance plan, savings may apply toward co-pay, co-insurance, or deductible. If you are eligible, you may be able to lower your out-of-pocket medication costs for DARZALEX В®. In addition to myeloma, funds are also available for patients with other types of blood cancer.Janssen CarePath Savings Program for DARZALEX В® Patients with private insurance and Medicare beneficiaries under Medicare Part B and/or Part D, Medicare Supplementary Health Insurance or Medicare Advantage are eligible if they meet the programвЂ™s income requirements. The LLS Co-Pay Assistance Program provides up to $5,000 annually for qualified patients, to help pay for prescription drug co-pays and health insurance premiums. Drugs such as bortezomib (VelcadeВ®), thalidomide (ThalomidВ®) and lenalidomide (RevlimidВ®) have shown promise in achieving remission and improving survival rates for some patients.Д«ecause these medicines are expensive, the Leukemia & Lymphoma Society has launched a new program to help myeloma patients who are having trouble affording their prescriptions. But the good news, LLS reports, is that doctors have begun making significant progress in treating and, in some cases, managing this difficult disease, thanks to a growing arsenal of new medications and therapies. Unfortunately, myeloma remains the most intractable blood cancer to cure, with just a 35% relative five-year survival rate in the United States.

Symptoms can include bone pain, fatigue, anemia and recurrent infections. It is most common in people age 50 or older and is often referred to as вЂњmultiple myelomaвЂќ because it usually involves multiple sites in the body at the time of diagnosis. What we do know is that myeloma is a cancer of the plasma cells that starts in the marrow and erodes the bones. Nobody seems to know the exact cause of myeloma, either.

In fact, a recent article in the LLS newsletter, eNewsline, notes that this life-threatening disease is twice as prevalent among black Americans than white Americans, and no one knows why. According to The Leukemia & Lymphoma Society (LLS), nurses need to know that myeloma, a serious and often deadly blood cancer, affects a disproportionate number of African Americans.

Lls copay assistance